<DOC>
	<DOCNO>NCT01364090</DOCNO>
	<brief_summary>This sudy determine whether shorten treatment hepatitis C feasible , safe effective patient current injection drug user receive opiate substitution therapy respond well treatment early .</brief_summary>
	<brief_title>A Collaborative Trial Injectors Individualized Treatment Genotype 2/3</brief_title>
	<detailed_description>The study evaluate feasibility , safety effectiveness shorten treatment hepatitis C genotypes 2/3 current injection drug user receive opiate substitution therapy . Treatment pegylated interferon alfa 2b ( directly observe ) ribavirin 12 week non-quantifiable ( &lt; 15 IU/ml detect &lt; 15 IU/ml undetected ) HCV RNA undetectable HCV RNA qualitative assay week 4 24 week quantifiable ( â‰¥15 IU/ml ) HCV RNA detectable HCV RNA qualitative assay week 4 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>18 year age chronic HCV infection HCV genotype 2/3 infection active injection drug use ( within 24 week prior consent ) currently receive opiate substitution therapy compensate liver disease negative pregnancy test ( within 24 hour first dose study medication ) effective contraception duration study write informed consent previous interferon ribavirin therapy investigation drug use 6 week prior first dose study medication infection HCV genotypes 2/3 HIV infection HBV infection ongoing severe psychiatric disease frequent drug use judge treat physician compromise treatment safety standard clinical medical exclusion treatment pegylated interferon alfa 2b ribavirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>treatment</keyword>
	<keyword>injection drug user receive opiate substitution therapy</keyword>
</DOC>